Cargando…

Does previous history of cancer or atypia predict histologic upgrade for pure intraductal papillomas diagnosed via core biopsy? A study of 490 cases at a single institution

BACKGROUND: Management of pure intraductal papillomas (IDP) without atypia diagnosed on core needle biopsy (CNB) remains controversial given highly variable rates of upgrade in the literature. AIM: We sought to identify clinical and histologic factors that predict upgrade to atypia or malignancy in...

Descripción completa

Detalles Bibliográficos
Autores principales: Alberty‐Oller, J. Jaime, Reyes, Sylvia, Moshier, Erin, Ru, Meng, Weltz, Sarah, Santos, Antonio, Pisapati, Kereeti, Port, Elisa, Jaffer, Shabnam
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8955065/
https://www.ncbi.nlm.nih.gov/pubmed/34729946
http://dx.doi.org/10.1002/cnr2.1481
_version_ 1784676247730651136
author Alberty‐Oller, J. Jaime
Reyes, Sylvia
Moshier, Erin
Ru, Meng
Weltz, Sarah
Santos, Antonio
Pisapati, Kereeti
Port, Elisa
Jaffer, Shabnam
author_facet Alberty‐Oller, J. Jaime
Reyes, Sylvia
Moshier, Erin
Ru, Meng
Weltz, Sarah
Santos, Antonio
Pisapati, Kereeti
Port, Elisa
Jaffer, Shabnam
author_sort Alberty‐Oller, J. Jaime
collection PubMed
description BACKGROUND: Management of pure intraductal papillomas (IDP) without atypia diagnosed on core needle biopsy (CNB) remains controversial given highly variable rates of upgrade in the literature. AIM: We sought to identify clinical and histologic factors that predict upgrade to atypia or malignancy in a large population. METHODS AND RESULTS: A retrospective review was performed of all cases of pure IDP diagnosed on CNB and then surgically excised at a single institution from 2008 to 2018. Clinical, radiologic, and pathologic factors were compared in the no upgrade, upgrade to atypia, or upgrade to cancer groups. Univariate analysis was performed comparing no upgrade and upgrade to cancer or atypia. Four hundred and thirty nine patients were identified with a total of 490 IDP and a median age of 50 years (range 16–85). Of these patients, 54 (12.3%) were upgraded to atypia after surgical excision and five (1.1%) were upgraded to cancer. The presence of multiple papillomas in a single patient was a significant predictor of upgrade to cancer or atypia (p < .01), as well as age over ≥55 years (p < .01) and a prior history of cancer (p < .01). No other clinical, radiologic and histologic factors were found to be significant predictors of upgrade. 40/439 (9.1%) patients in the total cohort had prior history of cancer, and of these, 2/40 (5%) were found to have a new cancer after excision. CONCLUSIONS: In patients with pure IDP on CNB, the upgrade rate to malignancy was 1.1%, while 12.3% were upgraded to atypia. The clinical significance of identifying atypia in a papilloma is unknown, especially in a patient with a prior history of atypia or cancer. However, the majority of patients who were upgraded to either atypia or cancer had no prior history of high‐risk or malignant breast disease and are therefore considered true clinical upgrades. As such excision for IDP should be considered.
format Online
Article
Text
id pubmed-8955065
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-89550652022-03-29 Does previous history of cancer or atypia predict histologic upgrade for pure intraductal papillomas diagnosed via core biopsy? A study of 490 cases at a single institution Alberty‐Oller, J. Jaime Reyes, Sylvia Moshier, Erin Ru, Meng Weltz, Sarah Santos, Antonio Pisapati, Kereeti Port, Elisa Jaffer, Shabnam Cancer Rep (Hoboken) Original Articles BACKGROUND: Management of pure intraductal papillomas (IDP) without atypia diagnosed on core needle biopsy (CNB) remains controversial given highly variable rates of upgrade in the literature. AIM: We sought to identify clinical and histologic factors that predict upgrade to atypia or malignancy in a large population. METHODS AND RESULTS: A retrospective review was performed of all cases of pure IDP diagnosed on CNB and then surgically excised at a single institution from 2008 to 2018. Clinical, radiologic, and pathologic factors were compared in the no upgrade, upgrade to atypia, or upgrade to cancer groups. Univariate analysis was performed comparing no upgrade and upgrade to cancer or atypia. Four hundred and thirty nine patients were identified with a total of 490 IDP and a median age of 50 years (range 16–85). Of these patients, 54 (12.3%) were upgraded to atypia after surgical excision and five (1.1%) were upgraded to cancer. The presence of multiple papillomas in a single patient was a significant predictor of upgrade to cancer or atypia (p < .01), as well as age over ≥55 years (p < .01) and a prior history of cancer (p < .01). No other clinical, radiologic and histologic factors were found to be significant predictors of upgrade. 40/439 (9.1%) patients in the total cohort had prior history of cancer, and of these, 2/40 (5%) were found to have a new cancer after excision. CONCLUSIONS: In patients with pure IDP on CNB, the upgrade rate to malignancy was 1.1%, while 12.3% were upgraded to atypia. The clinical significance of identifying atypia in a papilloma is unknown, especially in a patient with a prior history of atypia or cancer. However, the majority of patients who were upgraded to either atypia or cancer had no prior history of high‐risk or malignant breast disease and are therefore considered true clinical upgrades. As such excision for IDP should be considered. John Wiley and Sons Inc. 2021-11-02 /pmc/articles/PMC8955065/ /pubmed/34729946 http://dx.doi.org/10.1002/cnr2.1481 Text en © 2021 The Authors. Cancer Reports published by Wiley Periodicals LLC. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Articles
Alberty‐Oller, J. Jaime
Reyes, Sylvia
Moshier, Erin
Ru, Meng
Weltz, Sarah
Santos, Antonio
Pisapati, Kereeti
Port, Elisa
Jaffer, Shabnam
Does previous history of cancer or atypia predict histologic upgrade for pure intraductal papillomas diagnosed via core biopsy? A study of 490 cases at a single institution
title Does previous history of cancer or atypia predict histologic upgrade for pure intraductal papillomas diagnosed via core biopsy? A study of 490 cases at a single institution
title_full Does previous history of cancer or atypia predict histologic upgrade for pure intraductal papillomas diagnosed via core biopsy? A study of 490 cases at a single institution
title_fullStr Does previous history of cancer or atypia predict histologic upgrade for pure intraductal papillomas diagnosed via core biopsy? A study of 490 cases at a single institution
title_full_unstemmed Does previous history of cancer or atypia predict histologic upgrade for pure intraductal papillomas diagnosed via core biopsy? A study of 490 cases at a single institution
title_short Does previous history of cancer or atypia predict histologic upgrade for pure intraductal papillomas diagnosed via core biopsy? A study of 490 cases at a single institution
title_sort does previous history of cancer or atypia predict histologic upgrade for pure intraductal papillomas diagnosed via core biopsy? a study of 490 cases at a single institution
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8955065/
https://www.ncbi.nlm.nih.gov/pubmed/34729946
http://dx.doi.org/10.1002/cnr2.1481
work_keys_str_mv AT albertyollerjjaime doesprevioushistoryofcanceroratypiapredicthistologicupgradeforpureintraductalpapillomasdiagnosedviacorebiopsyastudyof490casesatasingleinstitution
AT reyessylvia doesprevioushistoryofcanceroratypiapredicthistologicupgradeforpureintraductalpapillomasdiagnosedviacorebiopsyastudyof490casesatasingleinstitution
AT moshiererin doesprevioushistoryofcanceroratypiapredicthistologicupgradeforpureintraductalpapillomasdiagnosedviacorebiopsyastudyof490casesatasingleinstitution
AT rumeng doesprevioushistoryofcanceroratypiapredicthistologicupgradeforpureintraductalpapillomasdiagnosedviacorebiopsyastudyof490casesatasingleinstitution
AT weltzsarah doesprevioushistoryofcanceroratypiapredicthistologicupgradeforpureintraductalpapillomasdiagnosedviacorebiopsyastudyof490casesatasingleinstitution
AT santosantonio doesprevioushistoryofcanceroratypiapredicthistologicupgradeforpureintraductalpapillomasdiagnosedviacorebiopsyastudyof490casesatasingleinstitution
AT pisapatikereeti doesprevioushistoryofcanceroratypiapredicthistologicupgradeforpureintraductalpapillomasdiagnosedviacorebiopsyastudyof490casesatasingleinstitution
AT portelisa doesprevioushistoryofcanceroratypiapredicthistologicupgradeforpureintraductalpapillomasdiagnosedviacorebiopsyastudyof490casesatasingleinstitution
AT jaffershabnam doesprevioushistoryofcanceroratypiapredicthistologicupgradeforpureintraductalpapillomasdiagnosedviacorebiopsyastudyof490casesatasingleinstitution